[Asia Economy Reporter Myung-Hwan Lee] Samsung Pharmaceutical is soaring amid a declining market on the morning of the 14th. This is interpreted as being influenced by the news of signing a pharmaceutical supply contract worth 37 billion KRW the previous day.
As of 9:58 AM today, Samsung Pharmaceutical is trading at 4,280 KRW, up 17.74% (645 KRW) from the previous trading day.
Samsung Pharmaceutical announced yesterday that it signed a pharmaceutical supply contract worth 36.9886 billion KRW with Ilhwa. The contract period is from the 13th of this month to December 31, 2026. The contract amount corresponds to 67.37% of last year's sales.
Under this contract, Samsung Pharmaceutical will exclusively supply 18 prescription drug items, including 'Doranjinju 50mg', to Ilhwa, and Ilhwa will exclusively sell them through domestic distribution channels. Ilhwa must guarantee the purchase of more than 90% of the expected annual sales. The contract includes a clause that allows Samsung Pharmaceutical to claim damages from Ilhwa if Ilhwa fails to meet the purchase guarantee condition.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
